Infectofos (Fosfomycin)

Fosfomycin blocks the MurA enzyme, which is essential for the first step of bacterial cell‑wall synthesis. By preventing the formation of peptidoglycan, the drug weakens the bacterial wall, leading to rapid cell lysis. This mechanism is distinct from β‑lactam antibiotics and remains effective against many resistant strains.

The dosage of Infectofos is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local guidelines. Healthcare professionals should follow the specific dosing recommendations provided in the product label or institutional protocol.

Safety data for intravenous fosfomycin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Infectofos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and assistance with import documentation.

The primary alternative to intravenous fosfomycin is often a carbapenem or a broad‑spectrum β‑lactam. Fosfomycin offers a unique mechanism that can be effective against some carbapenem‑resistant organisms, and it may be used as a carbapenem‑sparing option. However, susceptibility testing is essential to guide therapy.

Infectofos should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

Infectofos is administered by intravenous infusion under the supervision of qualified medical personnel. The infusion rate and duration are determined by the prescribing clinician, taking into account the patient’s renal function and the specific infection being treated.

Serious adverse events associated with fosfomycin include anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, severe hepatic dysfunction, acute renal failure, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are critical if any of these occur.

Patients with known hypersensitivity to fosfomycin or any component of the formulation should avoid Infectofos. Caution is also advised for individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those receiving drugs that may cause dangerous interactions, unless a risk‑benefit assessment justifies use.